Literature DB >> 10349862

Mazindol attenuates the 3,4-methylenedioxymethamphetamine-induced formation of hydroxyl radicals and long-term depletion of serotonin in the striatum.

M Shankaran1, B K Yamamoto, G A Gudelsky.   

Abstract

The formation of hydroxyl radicals following the systemic administration of 3,4-methylenedioxymethamphetamine (MDMA) was studied in the striatum of the rat by quantifying the stable adducts of salicylic acid and D-phenylalanine, namely, 2,3-dihydroxybenzoic acid (2,3-DHBA) and p-tyrosine, respectively. The repeated administration of MDMA produced a sustained increase in the extracellular concentration of 2,3-DHBA and p-tyrosine, as well as dopamine. The MDMA-induced increase in the extracellular concentration of both dopamine and 2,3-DHBA was suppressed in rats treated with mazindol, a dopamine uptake inhibitor. Mazindol also attenuated the long-term depletion of serotonin (5-HT) in the striatum produced by MDMA without altering the acute hyperthermic response to MDMA. These results are supportive of the view that MDMA produces a dopamine-dependent increase in the formation of hydroxyl radicals in the striatum that may contribute to the mechanism whereby MDMA produces a long-term depletion of brain 5-HT content.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10349862     DOI: 10.1046/j.1471-4159.1999.0722516.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  12 in total

Review 1.  Causes and consequences of methamphetamine and MDMA toxicity.

Authors:  Maria S Quinton; Bryan K Yamamoto
Journal:  AAPS J       Date:  2006-05-12       Impact factor: 4.009

2.  MDMA-induced neurotoxicity: long-term effects on 5-HT biosynthesis and the influence of ambient temperature.

Authors:  Esther O'Shea; Laura Orio; Isabel Escobedo; Veronica Sanchez; Jorge Camarero; Alfred Richard Green; Maria Isabel Colado
Journal:  Br J Pharmacol       Date:  2006-06-12       Impact factor: 8.739

3.  In vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery.

Authors:  Altaf S Darvesh; Richard T Carroll; Werner J Geldenhuys; Gary A Gudelsky; Jochen Klein; Charles K Meshul; Cornelis J Van der Schyf
Journal:  Expert Opin Drug Discov       Date:  2011-02       Impact factor: 6.098

Review 4.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

Review 5.  The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse.

Authors:  Bryan K Yamamoto; Jamie Raudensky
Journal:  J Neuroimmune Pharmacol       Date:  2008-08-15       Impact factor: 4.147

6.  Chronic unpredictable stress augments +3,4-methylenedioxymethamphetamine-induced monoamine depletions: the role of corticosterone.

Authors:  B N Johnson; B K Yamamoto
Journal:  Neuroscience       Date:  2009-02-03       Impact factor: 3.590

Review 7.  Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons.

Authors:  Gary A Gudelsky; Bryan K Yamamoto
Journal:  Pharmacol Biochem Behav       Date:  2007-10-16       Impact factor: 3.533

Review 8.  Developmental effects of 3,4-methylenedioxymethamphetamine: a review.

Authors:  Matthew R Skelton; Michael T Williams; Charles V Vorhees
Journal:  Behav Pharmacol       Date:  2008-03       Impact factor: 2.293

Review 9.  Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview.

Authors:  João Paulo Capela; Helena Carmo; Fernando Remião; Maria Lourdes Bastos; Andreas Meisel; Félix Carvalho
Journal:  Mol Neurobiol       Date:  2009-04-17       Impact factor: 5.590

10.  MDMA ("ecstasy"), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat.

Authors:  Kelly J Clemens; Petra S Van Nieuwenhuyzen; Kong M Li; Jennifer L Cornish; Glenn E Hunt; Iain S McGregor
Journal:  Psychopharmacology (Berl)       Date:  2004-03-17       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.